- Home
- MYGN vs ETO Comparison
MYGN vs ETO Comparison
Compare MYGN & ETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- ETO
- Stock Information
- Founded
- MYGN 1991
- ETO 2004
- Country
- MYGN United States
- ETO United States
- Employees
- MYGN N/A
- ETO N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ETO Investment Managers
- Sector
- MYGN Health Care
- ETO Finance
- Exchange
- MYGN Nasdaq
- ETO Nasdaq
- Market Cap
- MYGN 423.1M
- ETO 448.2M
- IPO Year
- MYGN 1995
- ETO N/A
- Fundamental
- Price
- MYGN $3.91
- ETO $26.56
- Analyst Decision
- MYGN Hold
- ETO
- Analyst Count
- MYGN 15
- ETO 0
- Target Price
- MYGN $15.14
- ETO N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- ETO 26.5K
- Earning Date
- MYGN 08-12-2025
- ETO 01-01-0001
- Dividend Yield
- MYGN N/A
- ETO 6.67%
- EPS Growth
- MYGN N/A
- ETO N/A
- EPS
- MYGN N/A
- ETO N/A
- Revenue
- MYGN $831,300,000.00
- ETO N/A
- Revenue This Year
- MYGN N/A
- ETO N/A
- Revenue Next Year
- MYGN $6.64
- ETO N/A
- P/E Ratio
- MYGN N/A
- ETO N/A
- Revenue Growth
- MYGN 7.38
- ETO N/A
- 52 Week Low
- MYGN $3.78
- ETO $19.85
- 52 Week High
- MYGN $29.30
- ETO $25.21
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- ETO 37.19
- Support Level
- MYGN $4.43
- ETO $27.44
- Resistance Level
- MYGN $4.83
- ETO $27.80
- Average True Range (ATR)
- MYGN 0.25
- ETO 0.28
- MACD
- MYGN -0.10
- ETO -0.12
- Stochastic Oscillator
- MYGN 9.32
- ETO 10.14
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About ETO Eaton Vance Tax-Advantage Global Dividend Opp
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.